ImmunityBio falls after posting Q2 loss
IBRX•Revenue beats estimates on Anktiva adoption
** Revenue rises 93.9% to $51.24 million from a year ago, and above expectations of $49.70 million
** IBRX attributes revenue growth to continued adoption of its bladder cancer drug Anktiva by U.S. urologists and strong market access
** Co says it expects multiple regulatory and clinical milestones over the next 12 months
** Including session's moves, IBRX has rallied about 260% YTD, significantly outperforming the Nasdaq's .IXIC 12.8% rise
Shares fall after wider-than-expected quarterly loss
** ImmunityBio Inc IBRX.O shares dip 3% to $6.94
** The biotech firm posts a Q2 loss of 22 cents per share, vs. estimates for a loss of 9 cents per share - LSEG data
** First-half net loss expands from $222.2 million in 2025 to $863.2 million in 2026
